CCR4 and adult T-cell leukemia/lymphoma: Mogamulizumab (Mog) is a humanized anti-CCR4 immunoglobulin G1 monoclonal antibody that has an almost 50% efficacy in patients with relapsed or refractory ATLL (103, 104).